Zhejiang Pharmaceuticals: Disclosure of Insider Trading Self-Check Status of Restricted Stock Incentive Plan by 2025

Zhejiang Pharmaceutical announced that the company approved the 2025 Restricted Stock Incentive Plan on October 27, 2025. According to regulations, the company conducted a self-examination of insider trading activities of individuals with knowledge of the incentive plan within the six months before the draft announcement. The results showed that some of the individuals under investigation bought and sold company stocks during the self-examination period based on their own market judgment, unrelated to the incentive plan, and did not engage in insider trading. No instances were found of individuals with insider information buying or selling stocks based on insider information, or engaging in insider trading activities.